Evvy

Evvy is a New York precision women's health startup building around a problem medicine spent too long treating as peripheral: the vaginal microbiome. Founded in 2020 by Priyanka Jain, Laine Bruzek, and Pita Navarro, the company combines at-home microbiome testing, AI-assisted interpretation, clinical care, and coaching into a single precision care platform. The signal is bigger than one test because Evvy says it has served more than 100,000 patients, supports more than 2,000 providers nationwide, and has raised more than $30M from investors including General Catalyst, Left Lane Capital, BoxGroup, RH Capital, US Fertility, and Labcorp.

The broader implication is straightforward: healthcare is moving toward systems that can turn overlooked biological data into repeatable clinical intelligence. Evvy is not just selling a report that leaves patients to interpret the fine print. It is trying to connect diagnostics, software, research, provider workflows, and patient support into a feedback loop that gets smarter as more women use it.

About Evvy

Evvy operates at the intersection of precision medicine, diagnostics, artificial intelligence, and women's health. The company's stated mission is to close the gender health gap by discovering and operationalizing overlooked female biomarkers, starting with the vaginal microbiome. That focus matters because women's health has historically received less research attention than comparable medical categories, creating gaps in diagnosis, treatment, and preventive care that show up in everyday clinical experience.

Evvy's flagship testing approach uses metagenomic sequencing, which analyzes a broader microbial community instead of checking only for a narrow list of known organisms. The company's vaginal healthcare platform connects those results to personalized recommendations, clinical care, and one-on-one coaching. The value is not raw data by itself; the value is making the data actionable for patients, providers, and researchers.

Why Evvy Matters Right Now

Healthcare increasingly rewards companies that own differentiated datasets and know how to apply them inside real care workflows. Evvy says its work has produced the world's largest vaginal microbiome dataset, a proprietary research asset that becomes more useful as additional patient outcomes, provider interactions, and clinical patterns are connected. That gives the company a different profile from digital health businesses built primarily on user experience or care navigation.

The compounding effect is the strategic point. Every diagnostic can expand the dataset, every patient can improve the evidence base, and every provider relationship can sharpen clinical usefulness. In a category where trial-and-error care has often been normalized, intelligent scale is more valuable than scale alone.

The Problem Evvy Is Solving

Millions of women deal with recurrent bacterial vaginosis, yeast infections, chronic urinary tract infections, and other vaginal health concerns that often involve repeated treatment cycles without a precise understanding of the underlying microbiome. Traditional care has frequently depended on symptoms, limited testing, and prescribing patterns that may treat the immediate issue without explaining why it keeps returning. Evvy is betting that deeper biological measurement can shift that experience from reactive treatment toward more personalized care.

That ambition extends beyond common vaginal health conditions. The company's research narrative points toward reproductive health, fertility, pregnancy outcomes, gynecologic disease, and broader microbiome science. Those are not small categories, and Evvy's positioning suggests the company wants to become infrastructure for how precision women's healthcare gets studied, delivered, and improved.

Market Context

Women's health has become a more visible investment category, but more capital does not automatically create better infrastructure. Evvy is interesting because it sits across several layers at once: diagnostics, clinical care, AI, healthcare data, and patient engagement. That combination makes the company harder to evaluate as a simple consumer health brand and more relevant as a potential precision medicine platform.

Scientific credibility is part of that platform story. Evvy reports research activity presented through organizations including the American College of Obstetricians and Gynecologists, the American Society for Reproductive Medicine, and the Infectious Diseases Society for Obstetrics and Gynecology. For investors, clinicians, and operators, those signals matter because healthcare markets do not reward narrative alone for very long.

Leadership and Team

Evvy's founding team brings together product, brand, and scientific leadership around a shared mission. Priyanka Jain serves as Co-Founder and CEO, Laine Bruzek serves as Co-Founder and Chief Marketing Officer, and Pita Navarro serves as Co-Founder and Chief Science Officer.

That leadership mix shapes the company's public posture. Evvy does not present itself as another wellness wrapper around generic lab testing. The company frames its work as a long-term effort to make historically ignored female biomarkers visible, measurable, and useful in care decisions.

Why Hiring Momentum Matters

Evvy is hiring across engineering, product, clinical, data, science, operations, marketing, and commercial functions through its careers page. In this context, hiring should be read as a market signal rather than employer-branding copy. Healthcare companies usually expand across that many functions when multiple systems are scaling at the same time: software, data, clinical operations, research, and commercialization.

For sophisticated operators, that pattern says more than a jobs page normally does. It suggests Evvy is moving beyond a single diagnostic product toward a broader precision healthcare platform with software, clinical services, research programs, and AI infrastructure working together. The company is recruiting for the machinery behind the model, not just the story around it.

What This Signals for Women's Health

The next generation of healthcare leaders may not be defined only by breakthrough therapies. They may also emerge by organizing fragmented biological information into actionable clinical intelligence. Evvy reflects that shift because its potential advantage comes from the combination of proprietary microbiome data, AI interpretation, clinical integration, patient engagement, and continuous learning.

That combination is becoming increasingly important across healthcare. Artificial intelligence can improve interpretation, but AI without differentiated data rarely creates durable advantage. Evvy is attempting to build both at the same time, which is why the company belongs in the conversation around precision medicine, healthcare AI, and the future of women's health infrastructure.

The Bigger Industry Shift

Healthcare has spent decades collecting information while struggling to connect it into decisions patients and providers can use. Precision medicine changes that standard by asking whether data can become clinically useful before frustration becomes the default patient experience. Evvy's work around the vaginal microbiome fits that broader shift because it starts with a category medicine has historically undermeasured and then builds a platform around making that measurement useful.

The companies creating lasting value in healthcare will likely own more than software, diagnostics, or services in isolation. They will build integrated ecosystems where each layer improves the next. Evvy is positioning itself inside that future, where precision women's healthcare is not a side category but a data-rich, clinically serious market with infrastructure still being built.